Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies
Kanellopoulos, Alexandros McIlroy, Graham Paneesha, Shankara Kaparou, Maria Kishore, Bhuvan Lovell, Richard Davies, David Xenou, Evgenia
Kanellopoulos, Alexandros
McIlroy, Graham
Paneesha, Shankara
Kaparou, Maria
Kishore, Bhuvan
Lovell, Richard
Davies, David
Xenou, Evgenia
Abstract
This European Society for Blood and Marrow Transplantation conference abstract reports that three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies.
MIDER Authors
Affiliations
Heart of England NHS Foundation Trust; University of Birmingham; South Warwickshire University NHS Foundation Trust
Citations
Altmetric:
Date
2018-11-19
Type
Conference Output
Subject
Collections
Citation
Kanellopoulos A, McIlroy G, Elmoamly DD, Xenou E, Horgan C, Kinsella F, Arbuthnot C, Borg A, Randall K, Ryann L, Collins K. Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab-based allogeneic stem cell transplants for haematological malignancies. Bone Marrow Transplantation. 2018;53:295. doi: 10.1038/s41409-018-0354-7.